(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that Enhertu has been approved in the European Union as an adjuvant treatment for adults with HER2‑positive early breast cancer who still have signs of invasive disease after initial chemotherapy and targeted therapy.
Astrazeneca said the approval marks the drug's first EU approval...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE